Safety Profile

Tirzepatide Side Effects & Safety

Tirzepatide shares a similar side effect profile to semaglutide but with slightly higher rates of GI effects due to stronger incretin activity.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Black Box Warning

Risk of thyroid C-cell tumors observed in rats. Human relevance unknown. Contraindicated in patients with personal or family history of MTC or MEN 2.

Side effects by severity

Serious1 effect

MTC risk

Same rodent data as GLP-1 monotherapy; black box warning.

Common6 effects

Nausea

18-33%

Dose-related; most intense during titration.

Diarrhea

15-23%

Usually mild to moderate.

Decreased appetite

11-21%

Expected pharmacological effect.

Vomiting

8-13%

More common at higher doses.

Constipation

9-17%

Responsive to hydration and fiber.

Abdominal pain

5-10%

Usually mild.

Uncommon2 effects

Injection site reactions

Mild erythema or pruritus.

Gallbladder disease

Particularly in setting of rapid weight loss.

Rare3 effects

Acute pancreatitis

Severe abdominal pain radiating to back requires immediate evaluation.

Hypersensitivity reactions

Rare angioedema and anaphylaxis reported.

Severe hypoglycemia

Increased risk with insulin or sulfonylureas.

Contraindications

Personal or family history of MTC
MEN 2 syndrome
Hypersensitivity to tirzepatide

Drug interactions

Insulin and sulfonylureas — may require dose reduction
Oral contraceptives — reduced oral contraceptive effectiveness for 4 weeks after starting; use additional method
Oral medications with narrow therapeutic index

Special populations

Not studied in pregnancy. Limited elderly data. Should not be used in pediatric populations.

Safety summary

Tirzepatide is generally well-tolerated with GI side effects predominating. Unique to tirzepatide is a warning about reduced oral contraceptive efficacy — patients using oral contraceptives should switch to non-oral contraception or add a barrier method during the first 4 weeks.

Frequently asked

Does tirzepatide affect birth control?

Yes — oral contraceptive effectiveness may be reduced for 4 weeks after starting tirzepatide. Use a non-oral contraceptive or add a barrier method during this period.